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Abstract: The most common subtypes of primary cutaneous T-cell lymphoma (CTCL) are 
mycosis fungoides and Sézary syndrome. Clinical manifestations and prognosis in CTCL 
are highly variable. Improving the management of this incurable disease with limited toxicity 
is an active area of research. Romidepsin is a novel, well-tolerated histone deacetylase inhibitor 
with promising activity against advanced stages of CTCL. In November 2009, it was approved 
by the US Food and Drug Administration for the treatment of CTCL in patients who have 
received at least one prior systemic therapy. This review focuses on the activity, pharmacology, 
and safety of romidepsin for the treatment of CTCL.
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Introduction
Cutaneous T-cell lymphoma (CTCL) is a rare group of mature T-cell lymphomas 
primarily presenting in the skin. Between 2000 and 3000 new cases of CTCL occur in 
the US each year, with mycosis fungoides (MF) being the predominant subtype.1 Skin 
manifestations of MF include patches, plaques, tumors, and erythroderma. MF is cat-
egorized as limited stage by plaques or patches limited to the skin (IA, IB, and IIA) and 
advanced stage by cutaneous tumors and involvement of the blood, lymph nodes, bone 
marrow, or visceral organs (IIB to IVB).2 Sézary syndrome (SS), the leukemic variant of 
MF, is characterized by generalized erythroderma and abnormal lymphoid cells in the 
blood.3 Patients with limited stage disease frequently have an indolent clinical course 
and may be effectively treated with skin-directed therapies, including topical nitrogen 
mustard or psoralen plus ultraviolet A therapy.4 Treatment of advanced stage disease 
includes systemic therapy with α interferon, bexarotene, photopheresis, denileukin 
diftitox, vorinostat, cytotoxic chemotherapy, or combined modality therapies. However, 
in most patients, responses are seldom durable. This has led to a need to develop new 
therapies with targeted mechanisms of action and acceptable safety profiles.
Romidepsin (ISTODAX® [Astellas Pharma Inc., Tokyo, Japan], depsipeptide, 
FR901228, FK228) is a promising new agent that has shown remarkable activity in 
the treatment of T-cell lymphomas in preclinical studies and early-phase clinical trials. 
In November 2009, it was granted approval by the US Food and Drug Administration 
(FDA) for the treatment of CTCL in patients who have received at least one prior 
systemic therapy. It belongs to the new class of antineoplastic agents known as histone 
deacetylase inhibitors (HDACis) that are known to affect gene and protein function 
by epigenetic modulation. Vorinostat, another HDACi, is approved in the US for the 
treatment of CTCL in patients who have failed at least two prior systemic therapies. Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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HDACis have shown remarkable signal of activity in some 
T-cell malignancies such as CTCL and peripheral T-cell 
lymphoma, and several of these agents, including belinostat, 
panobinostat, and entinostat, are in various stages of clinical 
trials. The results are summarized in Tables 1 and 2.
Discovery, structure,  
and mechanism of action
Romidepsin was isolated from the fermentation broth of a 
Gram-negative, nonsporing coccobacillus Chromabacte-
rium violaceum strain WB968 by Fujisawa Pharmaceutical 
Company in Japan in an effort to identify compounds that 
can selectively reverse the phenotype of the ras transformed 
cells.5,6 Romidepsin was found to have the ability to reverse 
the morphology of the Ha-ras transformed cells to a normal 
phenotype. Hence, it was isolated and purified and was found 
to be a colorless prism with the structure of (E)-(1S, 4S, 
10S, 21R)-7-[(Z)-ethylidene]-4, 21-diisopropyl-2-oxa-12, 
13-dithia-5, 8, 20, 23-tetraazabicyclo [8, 7, 6]-tricos-16-ene 
3,6,9,19,22-pentanone, as shown in Figure 1. It was lipo-
philic and possessed a unique noncystine disulfide linkage. 
Nakajima et al showed that romidepsin caused the arrest of 
the cell cycle at both G1 and G2/M phases and the induction 
of internucleosomal breakdown of chromatin characteris-
tic of apoptosis.7 They also demonstrated that it inhibited 
intracellular histone deacetylase activity, leading to marked 
accumulation of acetylated histone (H1, H2A, H2B, H3, and 
H4) in the cell, and established its role as a novel HDACi. 
Furumai et al demonstrated that romidepsin circulates in the 
serum in its inactive form and penetrates the cell membrane 
effectively given its hydrophobic nature.8 However, on enter-
ing the tumor cell, it gets converted to an active, reduced form 
(redFK) by intracellular antioxidants involving glutathione. 
It has been proposed that one of the sulfhydryl groups of the 
reduced form interacts with the zinc ions in the active site 
of the class I HDAC enzymes, leading to potent inhibition 
of enzymatic activity of both class I and II HDACs in vivo, 
but its activity against HDAC4 and HDAC6 class II enzymes 
remains weak. The prodrug form of romidepsin has a half-
life of .12 hours, whereas the redFK form has a half-life 
of 0.54 hours. This clearly demonstrates that romidepsin 
is quite stable in the prodrug form in blood, which may be 
responsible for its strong in vivo HDAC inhibition.
It is now well established that modulation of histone and 
protein acetylation alters pathways that promote   proliferation, 
angiogenesis, and survival in cancer cells. A common finding 
in malignant cells is the high level of expression of HDAC 
isoenzymes and a corresponding hypoacetylation of histones. 
HDACis work through myriad different mechanisms,   including 
i) upregulation of cell-dependent kinase (cdk) inhibitors like 
p21/p27 and downregulation of cyclinD1; ii) acetylation of non-
histone proteins, including STAT-3, RelA/p65, p53, HIF-1α, 
Bcl-6, and Hsp 90, in a way that modulates their activity and 
thus their ability to regulate cell growth and survival; iii) direct 
activation of apoptotic pathways by affecting the balance 
between the antiapoptotic proteins like Bcl-2 and the proapa-
pototic proteins like Bax and Bak; iv) enhanced production 
of reactive oxygen species along with increased thioredosin 
levels; v) enhanced antitumor immunity through enhancement 
of TRAIL or upregulation of antigen expression, which could 
facilitate cancer cell recognition; and vi)   disruption of DNA 
repair through acetylation or downregulation of proteins such 
as Ku70, Ku86, BRCA1, and RAD51.9,10 Despite these pleio-
tropic effects, it has been difficult to assign a precise mecha-
nistic basis to their anticancer effects in any particular tumor 
type, let alone CTCL. It is peculiar that romidepsin appears 
to have a class effect in CTCL in contrast to other subtypes 
of lymphoproliferative neoplasms. Gene expression profiling 
on paired tissue samples and studies of select biomarkers, 
including gene activation with HDACis, has shown that up 
to 5%–10% of the genome can be affected by HDACis. In 
one study, the genes that were consistently affected included 
Table 1 Summary of the histone deacetylase (HDAC) inhibitors tested in cutaneous T-cell lymphoma
Properties Vorinostat 
(Zolinza)
Depsipeptide 
(romidepsin)
Panobinostat 
(LBH589)
Belinostat 
(PXD101)
HDAC class 
specificity
i, ii, iv i, ii, iv i, ii, iv i, ii, iv
in vitro potencya μM nM nM μM
Half-life (h) 1.45  2.64 8 0.3–1.3
Route Oral intravenous Oral Oral/intravenous
Dose and schedule 400 mg/day; 
300 mg twice a day
14 mg/m2 on days 1, 
8, and 15
20 mg three times 
a week
1000 mg/m2; 30 min 
intravenously for  
5 days/3 weeks
Note: aReported range of drug concentration necessary for in vitro inhibition of HDAC in cell lines.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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genes affecting cell cycle (CCNDI, IGFI), apoptosis (septin10, 
TEF, SORBBS2), angiogenesis (GUCY1A1, ANGPT1), and 
immune modulation (LAIR1).11
Preclinical activity
Romidepsin demonstrated potent cytotoxicity against human 
tumor cell lines and in vivo efficacy against both human 
tumor xenografts and murine tumors.5,6 Many human tumors 
appear to be associated with the expression of activated ras 
genes. Romidepsin was found to reverse the morphology of 
the Ha-ras transfected mouse NIH/3T3 (Ras1) cells to that 
of the parent, thereby suggesting inhibitory effects on the 
growth of tumor cells and potential as an anticancer agent.5 
This was through a decrease in the mRNA expression of 
the c-myc oncogene in Ras1 cells, but it had no effect on 
H-ras mRNA expression, implying various other potential 
mechanisms such as activation of the Raf/MEK/ERK axis 
or the PI3K/Akt/GSK-3 pathway, which needs validation in 
preclinical and correlative clinical studies. In vitro, it induced 
cell cycle arrest in both G1 and G2/M phases and apoptosis 
in a number of human tumor cell lines such as A549, PC-9 
lung   adenocarcinoma, PC-1 and PC-10 lung squamous cell 
carcinoma, ADH, LX-1 small cell lung carcinoma, MKN28, 
MKN74 stomach adenocarcinoma, MCF-7, ZR-75–1 
Table 2 Outcomes of histone deacetylase inhibitors in CTCL
Outcome Vorinostat Romidepsin Panobinostat Belinostat
Phase ii
(Olsen et al)46
ii
(whittaker et al)36
ii
(Duvic et al)47
ii
(Foss et al)48
ORR 29.7% 34% 20% 25%
N 74 96 95 16
CR 1 6 4 (skin and CT) 1
PR 21 27 11 (skin, CR 2) 3
DoR 6.1 months 15 months NA NA
TTP 9.8 months 8 months NA NA
Approval status Approved as monotherapy  
for cutaneous manifestations  
of CTCL patients who have failed  
at least 2 prior systemic therapies 
Approved as monotherapy  
for CTCL patients who have  
failed at least 1 prior systemic  
therapy
Not yet approved  
as monotherapy in CTCL  
Ongoing Phase ii trials
Not yet approved as 
monotherapy in CTCL 
Ongoing Phase ii trials
Abbreviations: CR, complete response; CTCL, cutaneous T-cell lymphoma; DoR, duration of response; NA, not available; N, number of patients enrolled in the trial; 
ORR, overall response rate; PR, partial response; TTP, time to progression.
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Drug name
Phase
Registered indication
Mechanism of action
Route of administration
Chemical structure  
Romidepsin
Registered
Cutaneous T-cell lymphoma that has failed one prior systemic therapy
Histone deacetylation inhibition
Parenteral, intravenous   
Pivotal trials
 1.   Phase II multi-institutional trial of romidepsin as monotherapy for
       patients with cutaneous T-cell lymphoma (N = 71)
2.  Final results from a multicenter, international, pivotal study of
     romidepsin in refractory cutaneous T-cell lymphoma (N = 96) 
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  mammary adenocarcinoma, Colo201, and SW480 colon 
adenocarcinoma at low ng/mL concentrations.6 Romidepsin 
exhibited weak cytoxicity against human normal endothelial 
cell HE-9, mouse fibroblast Balb/c3T3, and NIH3T3 and 
demonstrated no activity against human and mouse normal 
fibroblast cells, thereby suggesting selectivity. Other in vitro 
studies have revealed antiproliferative effects of romidepsin 
against B-cell chronic lymphocytic leukemia (CLL) cell 
lines,12 T-cell lymphoma cells,13 and multiple myeloma cells.14 
In vivo, it was found to prolong the life of mice bearing murine 
ascitic tumors, murine leukemias, and melanoma and inhib-
ited the growth of murine solid tumors such as colon cancer, 
sarcomas, and human solid tumors implanted in normal and 
nude mice.6 When given intravenously every 4 days, it inhib-
ited the growth of several human tumor xenografts such as 
MX-1 breast carcinoma, LC-6 lung carcinoma, LU-65 large 
cell lung carcinoma, and SC-6 stomach adenocarcinoma.6 
This antitumor activity was confirmed by the National Cancer 
Institute (NCI), and the agent was assigned the NSC number 
NSC-630176 for further clinical development.
Romidepsin showed a lack of cross-resistance to sev-
eral commonly used cytotoxic agents such as vincristine, 
5-fluorouracil, mitomycin C, and cyclophosphamide and was 
identified as a P-glycoprotein (Pgp) and multidrug resistance-
associated protein (MRP-1) substrate by Xiao et al.15 It is 
well established that Pgp and MRP-1 are associated with 
resistance to anticancer drugs. With the help of a romidepsin-
resistant cell line (HCT15R) developed from HCT15 colon 
carcinoma, it was confirmed that efflux of romidepsin via Pgp 
induction is the major mechanism for acquired romidepsin 
resistance. These data need to be considered when romidepsin 
is used to pretreat patients who are receiving Pgp substrate 
drugs. This property also raises the possibility of combin-
ing romidepsin with Pgp inhibitors in developing treatment 
strategies for patients with CTCL or using Pgp inhibitors 
to reverse the resistance to romidepsin. As a substrate for 
  Pgp-mediated drug efflux, romidepsin would likely not 
penetrate into the central nervous system, as opposed to the 
other HDACis, which are not Pgp substrates.16,17
Johnstone et al demonstrated that romidepsin induced the 
accumulation of 4n DNA content, a G2 cell cycle checkpoint 
in the acute T-cell leukemia cell line CEM-CCRF, and caused 
apoptosis via activation of the intrinsic apoptotic pathway, 
which was accompanied by the cleavage and activation of 
caspase-2 and Bid.18 Romidepsin-induced mitochondrial 
damage and apoptosis were inhibited by overexpression 
of Bcl-2 but not by the polycaspase inhibitor (zVAD-
fmk). Moreover, induction of a G1-S checkpoint through 
overexpression of p16INK4A or suppression of de novo protein 
synthesis inhibited romidepsin-induced cell death. While 
romidepsin induced the activation of the proapoptotic 
Bcl-2 protein, Bid cleavage in response to romidepsin was 
significantly attenuated by zVAD-fmk. Bid lies upstream 
of mitochondrial membrane disruption and is an important 
proapoptotic molecule. This effect has not been demonstrated 
with other HDACis such as oxamflatin or SAHA (vorinostat), 
demonstrating the ability of these drugs to induce apoptosis in 
the absence of activation of certain caspases and highlighting 
functional differences between these structurally dissimilar 
compounds that are thought to have similar intracellular 
  targets. It was also found that romidepsin was a substrate of 
Pgp and hence less effective against Pgp-expressing tumor 
cells as opposed to oxamflatin and SAHA. Subsequently, 
  Johnstone et al used a Eμ-myc mouse model of B-cell 
lymphoma and showed that romidepsin had the ability 
to kill Eμ-myc lymphomas that overexpress Bcl-2 with 
delayed kinetics of cell death and could mediate therapeutic 
responses against these lymphomas.19 Of interest, they noted 
that Eμ-myc cells that overexpressed Bcl-XL were resistant 
to romidepsin as opposed to SAHA, thereby supporting the 
hypothesis that HDACis may have subtle yet potentially 
important differences in molecular activities.
Pharmacokinetics and 
pharmacodynamics of romidepsin
The current infusion schedule of administering romidepsin 
over 4 hours was based on the safety and efficacy of the 4-hour 
intravenous infusion over the 24-hour infusion observed in 
Beagle dogs and rats, following which this infusion time was 
incorporated for further studies in Phase I clinical trials.20,21 
Two Phase I trials were carried out simultaneously to deter-
mine the maximum tolerated dose (MTD) and toxicity profile 
of the 4-hour infusion of romidepsin and to characterize its 
pharmacokinetics. In the first trial performed by investigators 
at the NCI, the agent was given intermittently on a day 1 and 
day 5 schedule every 21 days.22 Thirty-seven patients with 
advanced or primary refractory neoplasms were administered 
the drug at that schedule. Based on the preclinical toxicology 
data, the starting dose of the trial was chosen as 1 mg/m2, 
and dose escalations proceeded through a total of eight dose 
levels to a maximum of 24.9 mg/m2. The MTD was defined 
at 17.8 mg/m2. Biologically active serum concentrations 
were achieved with this dose, and one partial response was 
observed. Dose-limiting toxicities (DLTs) included grade 3 
fatigue (three patients), grade 3 nausea and vomiting (one 
patient), grade 4 thrombocytopenia (two patients), and grade Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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4 cardiac arrhythmia (one patient, atrial fibrillation). The mean 
volume of distribution, clearance, distribution half-life (t1/2α), 
and elimination half-life (t1/2β) at a dose of 17.8 mg/m2 were 
8.6 L/m2, 11.6 L/h/m2, 0.42 hours, and 8.1 hours, respectively. 
The mean maximum plasma concentration (Cmax) at the MTD 
dose was 472.6 ng/mL. Furthermore, romidepsin pharma-
cokinetics was not significantly different when comparing the 
first cycle of a dose level with a subsequent cycle of the same 
dose. As expected, an increased dose led to increased Cmax 
and area under the curve (AUC). Pharmacokinetics was not 
affected by repeated dosing. In general, romidepsin was well 
tolerated. The significant cardiac toxicity seen in preclinical 
studies was not observed, and the dose suggested for Phase II 
was 17.8 mg/m2 administered on day 1 and day 5 of a 21-day 
cycle. The other Phase I trial conducted at the NCI utilized a 
different schedule in which romidepsin was administered as a 
4-hour infusion given weekly for 3 weeks followed by 1 week 
of rest in 33 patients with advanced cancers, including colorec-
tal, breast, bladder, sarcoma, and others. This trial established 
14 mg/m2 as the MTD dose, as no significant cardiac or skin 
toxicity was observed with this dose and schedule.23 The DLTs 
continued to be grade 3 thrombocytopenia and grade 3 fatigue, 
as seen in the earlier study. A romidepsin dose and schedule of 
14 mg/m2 given on days 1, 8, and 15 of a 21-day cycle were 
established as the Phase II dose for further investigation.
Pharmacokinetic analysis was performed on 98 patients 
enrolled in the NCI-sponsored Phase II multicenter clinical 
trial of romidepsin in patients with CTCL in whom the drug 
was administered at 14 mg/m2 or 18 mg/m2 on day 1   during 
their first treatment cycle.24 Using a noncompartmental 
analysis for the first dose, the mean half-life (2.95 hours) 
and observed clearance (9.6 h/m2) were comparable with 
previously reported parameters in the Phase I studies. After a 
4-hour infusion, romidepsin was rapidly eliminated from the 
circulation with a short half-life of ∼3.5 hours, as observed in 
other studies. Owing to this rapid distribution and clearance, 
resulting in plasma concentrations below the limit of quantita-
tion, terminal elimination rates (k el) could not be calculated. 
Romidepsin is extensively metabolized in vivo, primarily 
by the cytochromes P450 (CYP) 3A4, and to a lesser extent 
by the CYP3A5, and eliminated through bile and excreted 
in feces.25,26 Drug–drug interactions to be considered when 
administering romidepsin include any strong CYP3A4 or 
CYP3A5 inhibitors, such as ketoconazole, which has been 
shown to significantly lower romidepsin metabolism in vitro. 
Two-compartment population modeling was carried out to 
explore the effects of polymorphic variations in CYP3A4, 
CYP3A5, SLCO1B3, and ABCB1, all of which encode genes 
thought to be involved in the metabolism of romidepsin. 
Despite some minor interindividual variability, no statistical 
differences in romidepsin pharmacokinetic parameters were 
found between patients with wild-type genes and those with 
polymorphisms.
Pharmacodynamic studies have revealed the ability 
of serum from patients treated with romidepsin to induce 
cell cycle arrest and confirmed the histone acetylation 
increase in circulating peripheral blood mononuclear cells 
(PBMCs).27 The maximal accumulation of acetyl H3 his-
tones in PBMCs occurred at 4 hours after the end of the 
romidepsin infusion. Increased histone acetylation has also 
been reported in post-treatment biopsies. Other studies have 
also reported that in patients with acute myelogenous leuke-
mia (AML) and CLL treated with 13 mg/m2 of romidepsin 
intravenously on days 1, 8, and 15, HDAC inhibition and 
histone acetylation of at least 100% were observed, and the 
levels of H3 and H4 histone deacetylation were higher at 
the 4-hour time point than 24 hours in the CLL and AML 
cell lysates. Additionally, an increase in p21 expression 
occurred concurrently with H4 histone acetylation of the 
p21 promoter.28 In an attempt to find meaningful biomark-
ers of response to romidepsin, the molecular endpoints of 
romidepsin infusion were evaluated in 61 patients enrolled 
in the Phase II trial of romidepsin.29 They were identified as 
laboratory parameters modified by romidepsin and included 
histone H3 acetylation and ABCB1 gene expression in 
PMBCs, ABCB1 gene expression in tumor biopsy samples, 
and blood fetal hemoglobin (HbF) levels, all of which were 
increased   following romidepsin treatment. A   somewhat 
lower   proportion of patients   demonstrated increased 
ABCB1 expression in PBMCs. When each surrogate was 
evaluated for association with either PK parameters or 
disease response, it was noted that the increase in histone 
acetylation measured in PBMCs at 24 hours correlated with 
Cmax and AUC and inversely correlated with clearance. 
In addition, histone acetylation in PBMCs at the 24-hour 
time point appeared to correlate with response, despite a 
lack of a statistically significant correlation between PK 
parameters and response. There was no correlation between 
the levels of ABCB1 induction and pharmacokinetic param-
eters, nor was there an association between induction of 
ABCB1 in biopsy specimens and disease response. In total, 
60% of patients also had a greater than four-fold increase in 
circulating HbF detected in blood. Although this was cor-
related with response, it was also associated with increased 
time on study. These data suggest that for romidepsin, drug 
exposure dependent on drug clearance and drug activation Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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are important determinants of response, consistent with 
data from other HDACis.
Clinical activity of romidepsin  
in T -cell lymphomas
The first Phase I clinical trial of romidepsin was conducted 
in 2001 at the NCI by Piekarz et al and included four patients 
with refractory T-cell lymphomas (two patients with SS, one 
patient with tumor-stage CTCL, and one patient with unspeci-
fied peripheral T-cell lymphoma).30 The dosing schedule 
consisted of romidepsin administered at a dose of 12.7 mg/m2 
or 17.8 mg/m2 as a 4-hour intravenous infusion on days 1 
and 5 of a 21-day cycle, as described previously. To confirm 
biological activity, histone acetylation assays were performed 
on patients’ PBMCs. Responses were scored according to the 
World Health Organization criteria. Both patients with SS 
who were refractory to conventional chemotherapy agents 
had a rapid decrease in the percentage of circulating Sézary 
cells along with improvement in the skin erythema and edema 
following treatment with romidepsin. The first SS patient 
was removed from the study due to persistent methicillin-
resistant Staphylococcus aureus infection, and the second SS 
patient was removed after five cycles because of erythema 
and pruritus. There was rapid clearing of all tumors after 
six cycles of treatment with romidepsin in the third patient, 
whereas the fourth patient with peripheral T-cell lymphoma 
was declared to be in complete remission after the eighth 
cycle of romidepsin, with complete disappearance of his 
skin lesions and diffuse adenopathy. At the end of this trial, 
it was concluded that romidepsin demonstrated significant 
clinical activity in the treatment of T-cell lymphomas and 
needed further investigation in a Phase II trial.
Based on the favorable responses observed in patients 
with CTCL during Phase I testing, a Phase II trial to evalu-
ate the efficacy of romidepsin in these patients was initi-
ated at the NCI and extended to other centers after initial 
encouraging observations.31 A total of 71 patients with 
relapsed,   refractory, or advanced CTCL with either MF or 
SS who had no more than two prior cytotoxic chemotherapy 
regimens were enrolled, although there was no restriction on 
the number of prior systemic biologic therapies such as ste-
roids, retinoids, monoclonal antibodies, or topical therapies. 
A majority of the 71 patients had advanced disease (stage IIB 
to IVB) as follows: stage IVA (n = 28), stage IVB (n = 13), 
stage IIB (n = 15), stage IB (n = 6), stage IIIA and IIIB disease 
(n = 3), stage IIA (n = 2), and one patient alone had stage IA 
disease. The median number of prior therapies was four 
(0–14), including psoralen plus ultraviolet therapy, retinoids, 
radiation, total skin electron beam, photopheresis, interferon, 
and single or combination chemotherapy agents. Romidepsin 
was administered as a 4-hour intravenous infusion at the 
dose 14 mg/m2 on days 1, 8, and 15 of a 28-day schedule. 
The average number of cycles received by the patients was 
four (1–72), and the median number of doses was 12 (2–141). 
The response criterion used in this study was a composite 
score comprising the disease compartment that was involved, 
ie, skin, lymph nodes, or marrow. Disease in skin or viscera 
was assessed by Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria,32 lymph node involvement was 
assessed using International Working Group Guidelines 
(IWGG),33 and bone marrow involvement was recorded 
as present or absent. Generalized erythroderma was scored as 
present or absent. According to the RECIST criteria, size of 
skin lesions was documented by color photography including 
a ruler. The overall response rate for the group of 71 patients 
was 34% (23%–46%) with four complete responses (7%) 
and 20 (28%) partial responses observed. Stable disease was 
noted in 26 patients (38%). The median duration of response 
was notable at 13.7 months (range 1–66+ months). Among 
the patients with a major response (complete or partial), the 
median time to response was 2 months (range 1–6 months). 
The median time to progression was 15.1 months for patients 
with a major response and 5.9 months for patients with stable 
disease. One of the striking features of romidepsin was the 
long duration of response noted that extended beyond 3 years, 
which was observed in some patients even after discontinu-
ation of the drug. The complete responders included one 
patient with MF and three patients with SS. Among the 
62 patients with stage IV disease, 18 patients (29%) achieved 
a complete or partial response. Overall, the drug was well 
tolerated, with toxicities similar to those observed in Phase I 
trials, such as fatigue (41%), nausea (52%), vomiting (20%), 
anorexia (21%), leukopenia (31%), granulocytopenia (37%), 
lymphopenia (21%), thrombocytopenia (39%), and anemia 
(37%). Hematologic abnormalities returned to baseline by 
the next cycle. Asymptomatic T-wave flattening (71%) or 
ST segment depression (9%) was observed, with no evidence 
of cardiac damage. Of note, a median increase of 14 ms in 
the QT interval was seen with 0.2% of .2000 electrocardio-
grams, demonstrating a QTcB (Bazett’s correction) interval 
of more than 500 ms.
One of the major drawbacks of this study was the tools 
used to assess response. The RECIST criteria for solid tumors 
and the IWGG for lymphomas used in this trial give inac-
curate estimations of the disease burden in skin or blood. 
The Severity-Weighted Assessment Tool (SWAT) score Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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developed by Stevens et al34 uses the principle of grid-point 
counting and gives a more comprehensive, dynamic, and 
accurate measurement of the skin disease burden in MF.35 
This score represents the product of the percentage total 
body surface area (%TBSA) involvement of each lesion 
type (patch, plaque, and tumor or ulceration), multiplied by 
a weighting factor: SWAT = (patch %TBSA × 1) + (plaque 
%TBSA × 2) + (tumor or ulcer %TBSA × 3) within 12 body 
regions. The three weighted subtotals are added in order 
to determine the total score. It captures overall physical 
impressions of disease status on a continuous dimensionless 
numerical scale, thereby providing a defined, objective, and 
sensitive measure and hence is regarded as the best scoring 
system for skin disease in CTCL.
While the NCI study was being undertaken, Gloucester 
Pharmaceuticals started a parallel single-arm, open-label, 
prospective, Phase II trial of romidepsin in patients with pre-
treated CTCL. It was a multicenter trial involving 33 centers 
in eight countries.36 Ninety-six patients (59 with MF and 37 
with SS) were enrolled in the study and were administered 
romidepsin at the dose of 14 mg/m2 as a 4-hour infusion on 
days 1, 8, and 15 of each 28-day cycle for up to six cycles 
with the option of extension of treatment in those with stable 
disease or response. Enrolled patients had the following char-
acteristics: stage IVA (n = 24), stage III (n = 23), stage IIB 
(n = 21), stage IIA (n = 13), and stage IB (n = 15). The median 
number of prior therapies was four (1–11), which included 
skin-directed and systemic agents. This study employed a 
rigorous composite endpoint, which included the SWAT 
and erythroderma scores along with the RECIST criteria 
for the assessment of nodal disease and flow cytometry for 
changes in peripheral blood tumor burden to assess responses 
to romidepsin. Pruritus was reported monthly by the patients 
using a 100 mm visual analog scale (VAS).37,38 These various 
scores and scales were felt to be a better marker of overall 
meaningful tumor response. The primary endpoint of overall 
response rate was 34%, including six complete responses 
and 20 partial responses, with responses seen in all stages 
and all compartments of the disease (skin, blood, and lymph 
nodes). Of the 37 SS patients, 12 patients (32%) had a 
response to romidepsin, including two complete responses. 
A rapid, dramatic reduction in number of circulating Sézary 
cells was observed. There was a $50% reduction in SWAT 
and/or erythroderma scores in 38 patients (40%). The median 
duration of response was 15 months (range 0–19.8+ months) 
with a time to response of 2 months (range 0.9–4.8 months) 
and median time to complete response of 4 months (range 
0.9–6.9 months). Ninety-two percent of the patients showed 
improvement in their pruritus score. Of note, clinically mean-
ingful improvement in pruritus (assessed by VAS decrease 
of $30 mm or a score of 0 for 2 consecutive days) was 
observed in 28 (43%) patients. No serious adverse events 
were noted, with gastrointestinal intolerance and asthenia 
being the most common toxicities, and most of those were 
mild (grade 1 or 2). A clinically insignificant change in QTc 
interval was seen, which was attributed to antiemetics rather 
than to the drug per se.
These noteworthy results from two parallel, prospective, 
single-arm, multicenter trials were presented to the FDA and led 
to the approval of this agent in patients with advanced, refrac-
tory CTCL. The outcomes of major clinical trials of romidepsin 
as monotherapy have been summarized in Table 3.
Toxicities of romidepsin  
that deserve attention
Cardiac toxicity associated with HDACi therapy has been 
the focus of attention in all clinical trials involving these 
agents and appears to be a class effect. When romidepsin was 
administered at the dose of 1 mg/kg or 2 mg/kg as a 4-hour 
intravenous infusion on days 1, 5, and 9 or 2 mg/kg as a 
24-hour infusion on day 1 in Beagle dogs at the NCI, mortal-
ity occurred in all four dogs that received the 24-hour infusion 
and in one of the dogs that received the dose of 2 mg/kg over 
4 hours. Lymphoid atrophy was noted in all three treatment 
groups.20 This suggested efficacy of the 4-hour infusion 
and demonstrated toxicity of the 24-hour infusion. At very 
high doses, hemorrhages were detected in multiple organs, 
  including the heart. Neither   electrocardiogram abnormalities 
nor cardiac hemorrhages were observed when depsipeptide 
was infused over 4 hours. No cardiac lesions were detected in 
rats treated with very high doses.21 Unpublished observations 
of QT interval prolongation and ST segment abnormalities 
were observed in the Beagle dogs treated with rapid infusions 
of romidepsin. This and similar asymptomatic electrocardio-
graphic abnormalities noted in Phase I clinical trials involving 
a 4-hour infusion led to the incorporation of intensive cardiac 
monitoring in the Phase II trial for CTCL.39 Cardiac studies 
such as serial electrocardiograms, cardiac enzymes, multiple 
gated acquisition scans, echocardiograms, baseline 24-hour 
Holter analysis, and telemetry monitoring were performed 
during the first dose of the first cycle. Cardiac studies from 
282 cycles and 736 doses of romidepsin involving 2051 
electrocardiograms and 161 left ventricular ejection frac-
tion evaluations were reviewed. Although T-wave flattening 
(grade 1) and ST segment depression (grade 2) were observed 
in more than half of the electrocardiograms post-treatment, Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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Dovepress
44
Jain and Zain
T
a
b
l
e
 
3
 
S
u
m
m
a
r
y
 
o
f
 
m
a
j
o
r
 
c
l
i
n
i
c
a
l
 
t
r
i
a
l
s
 
p
e
r
f
o
r
m
e
d
 
t
o
 
d
a
t
e
 
w
i
t
h
 
r
o
m
i
d
e
p
s
i
n
 
a
s
 
a
 
s
i
n
g
l
e
 
a
g
e
n
t
T
r
i
a
l
E
l
i
g
i
b
i
l
i
t
y
D
o
s
e
 
a
n
d
 
s
c
h
e
d
u
l
e
R
e
s
u
l
t
s
T
o
x
i
c
i
t
y
C
o
n
c
l
u
s
i
o
n
P
h
a
s
e
 
i
 
(
P
i
e
k
a
r
z
 
e
t
 
a
l
)
3
0
C
T
C
L
 
P
T
C
L
1
2
.
7
 
m
g
/
m
2
 
o
r
 
1
7
.
8
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
 
a
n
d
 
5
 
e
v
e
r
y
 
3
 
w
e
e
k
s
3
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
C
T
C
L
 
h
a
d
 
P
R
 
a
n
d
 
 
1
 
p
a
t
i
e
n
t
 
w
i
t
h
 
P
T
C
L
 
h
a
d
 
C
R
N
A
R
o
m
i
d
e
p
s
i
n
 
i
s
 
a
c
t
i
v
e
 
i
n
 
T
-
c
e
l
l
 
l
y
m
p
h
o
m
a
P
h
a
s
e
 
i
 
(
S
a
n
d
o
r
 
e
t
 
a
l
)
2
2
v
a
r
i
e
t
y
 
o
f
 
s
o
l
i
d
 
t
u
m
o
r
 
m
a
l
i
g
n
a
n
c
i
e
s
D
o
s
e
 
e
s
c
a
l
a
t
i
o
n
 
f
r
o
m
 
1
 
m
g
/
m
2
 
t
o
 
2
4
.
9
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
 
a
n
d
 
5
 
e
v
e
r
y
 
3
 
w
e
e
k
s
1
 
p
a
t
i
e
n
t
 
w
i
t
h
 
R
C
C
 
h
a
d
 
P
R
 
a
n
d
 
 
8
 
p
a
t
i
e
n
t
s
 
h
a
d
 
S
D
 
o
u
t
 
o
f
 
3
7
 
p
a
t
i
e
n
t
s
F
a
t
i
g
u
e
,
 
n
a
u
s
e
a
,
 
v
o
m
i
t
i
n
g
,
 
a
n
d
 
t
r
a
n
s
i
e
n
t
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
M
T
D
 
o
f
 
d
e
p
s
i
p
e
p
t
i
d
e
 
w
a
s
 
1
7
.
8
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
 
a
n
d
 
5
 
e
v
e
r
y
 
3
 
w
e
e
k
s
P
h
a
s
e
 
i
 
(
B
y
r
d
 
e
t
 
a
l
)
2
8
C
L
L
 
 
A
M
L
1
3
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
,
 
8
,
 
a
n
d
 
 
1
5
 
e
v
e
r
y
 
4
 
w
e
e
k
s
A
n
t
i
t
u
m
o
r
 
a
c
t
i
v
i
t
y
 
s
e
e
n
 
b
u
t
 
n
o
 
 
C
R
 
o
r
 
P
R
 
i
n
 
2
0
 
p
a
t
i
e
n
t
s
F
a
t
i
g
u
e
,
 
n
a
u
s
e
a
,
 
a
n
d
 
c
o
n
s
t
i
t
u
t
i
o
n
a
l
 
s
y
m
p
t
o
m
s
H
D
A
C
 
i
n
h
i
b
i
t
i
o
n
 
o
b
s
e
r
v
e
d
 
b
u
t
 
t
o
o
 
t
o
x
i
c
 
a
t
 
t
h
i
s
 
s
c
h
e
d
u
l
e
P
h
a
s
e
 
i
i
 
(
P
a
r
k
e
r
 
e
t
 
a
l
)
4
9
M
e
t
a
s
t
a
t
i
c
 
h
o
r
m
o
n
e
-
r
e
f
r
a
c
t
o
r
y
 
p
r
o
s
t
a
t
e
 
c
a
n
c
e
r
1
3
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
,
 
8
,
 
a
n
d
 
 
1
5
 
e
v
e
r
y
 
4
 
w
e
e
k
s
1
 
r
a
d
i
o
l
o
g
i
c
a
l
 
P
R
 
i
n
 
3
1
 
p
a
t
i
e
n
t
s
N
a
u
s
e
a
,
 
f
a
t
i
g
u
e
,
 
v
o
m
i
t
i
n
g
D
i
s
e
a
s
e
 
c
o
n
t
r
o
l
 
r
a
t
e
 
o
f
 
1
4
%
.
 
N
o
 
g
r
a
d
e
 
4
 
t
o
x
i
c
i
t
y
P
h
a
s
e
 
i
i
 
(
S
t
a
d
l
e
r
 
e
t
 
a
l
)
5
0
R
e
f
r
a
c
t
o
r
y
 
m
e
t
a
s
t
a
t
i
c
 
R
C
C
1
3
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
,
 
8
,
 
a
n
d
 
 
1
5
 
e
v
e
r
y
 
4
 
w
e
e
k
s
1
 
C
R
 
a
n
d
 
1
 
P
R
 
o
u
t
 
o
f
 
2
9
 
p
a
t
i
e
n
t
s
F
a
t
i
g
u
e
,
 
n
a
u
s
e
a
,
 
v
o
m
i
t
i
n
g
,
 
a
n
e
m
i
a
N
o
 
a
c
t
i
v
i
t
y
 
i
n
 
t
h
i
s
 
p
o
p
u
l
a
t
i
o
n
 
a
t
 
t
h
i
s
 
d
o
s
e
 
a
n
d
 
s
c
h
e
d
u
l
e
P
h
a
s
e
 
i
i
 
(
w
h
i
t
e
h
e
a
d
 
e
t
 
a
l
)
5
1
M
e
t
a
s
t
a
t
i
c
 
c
o
l
o
r
e
c
t
a
l
 
c
a
n
c
e
r
1
3
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
,
 
8
,
 
a
n
d
 
 
1
5
 
e
v
e
r
y
 
4
 
w
e
e
k
s
N
o
 
r
e
s
p
o
n
s
e
F
a
t
i
g
u
e
,
 
a
n
o
r
e
x
i
a
N
o
 
a
c
t
i
v
i
t
y
 
i
n
 
t
h
i
s
 
p
o
p
u
l
a
t
i
o
n
 
a
t
 
t
h
i
s
 
d
o
s
e
 
a
n
d
 
s
c
h
e
d
u
l
e
P
h
a
s
e
 
i
i
 
(
P
i
e
k
a
r
z
 
e
t
 
a
l
)
3
1
C
T
C
L
1
8
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
 
a
n
d
 
 
5
 
e
v
e
r
y
 
3
 
w
e
e
k
s
4
 
C
R
 
a
n
d
 
2
0
 
P
R
 
i
n
 
7
1
 
p
a
t
i
e
n
t
s
F
a
t
i
g
u
e
,
 
n
a
u
s
e
a
,
 
t
r
a
n
s
i
e
n
t
 
c
y
t
o
p
e
n
i
a
s
O
n
e
 
o
f
 
t
h
e
 
t
r
i
a
l
s
 
t
h
a
t
 
l
e
d
 
t
o
 
t
h
e
 
a
p
p
r
o
v
a
l
 
o
f
 
r
o
m
i
d
e
p
s
i
n
 
i
n
 
C
T
C
L
P
h
a
s
e
 
i
i
 
(
w
h
i
t
t
a
k
e
r
 
e
t
 
a
l
)
3
6
C
T
C
L
1
8
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
 
a
n
d
 
 
5
 
e
v
e
r
y
 
3
 
w
e
e
k
s
6
 
C
R
 
a
n
d
 
2
7
 
P
R
 
i
n
 
9
6
 
p
a
t
i
e
n
t
s
G
i
 
i
n
t
o
l
e
r
a
n
c
e
 
a
n
d
 
a
s
t
h
e
n
i
a
T
h
e
 
p
i
v
o
t
a
l
 
t
r
i
a
l
 
t
h
a
t
 
s
u
p
p
o
r
t
e
d
 
t
h
e
 
F
D
A
 
a
p
p
r
o
v
a
l
 
o
f
 
r
o
m
i
d
e
p
s
i
n
 
f
o
r
 
C
T
C
L
P
h
a
s
e
 
i
i
 
(
N
i
e
s
v
i
z
k
y
 
e
t
 
a
l
)
5
2
R
e
f
r
a
c
t
o
r
y
 
m
u
l
t
i
p
l
e
 
m
y
e
l
o
m
a
1
3
 
m
g
/
m
2
 
o
n
 
d
a
y
s
 
1
,
 
8
,
 
a
n
d
 
 
1
5
 
e
v
e
r
y
 
4
 
w
e
e
k
s
N
o
 
o
b
j
e
c
t
i
v
e
 
r
e
s
p
o
n
s
e
s
 
i
n
 
1
3
 
p
a
t
i
e
n
t
s
 
e
x
c
e
p
t
 
s
t
a
b
i
l
i
z
a
t
i
o
n
 
o
f
 
M
-
p
r
o
t
e
i
n
 
i
n
 
4
 
s
e
c
r
e
t
o
r
y
 
M
M
 
p
a
t
i
e
n
t
s
.
 
 
i
m
p
r
o
v
e
d
 
h
y
p
e
r
c
a
l
c
e
m
i
a
 
a
n
d
 
p
a
i
n
 
i
n
 
5
 
a
n
d
 
2
 
p
a
t
i
e
n
t
s
,
 
r
e
s
p
e
c
t
i
v
e
l
y
N
a
u
s
e
a
,
 
f
a
t
i
g
u
e
,
 
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
R
o
m
i
d
e
p
s
i
n
 
a
s
 
s
i
n
g
l
e
 
a
g
e
n
t
 
i
s
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
,
3
0
%
 
r
e
s
p
o
n
s
e
 
r
a
t
e
 
i
n
 
M
M
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
M
L
,
 
a
c
u
t
e
 
m
y
e
l
o
i
d
 
l
e
u
k
e
m
i
a
;
 
C
L
L
,
 
c
h
r
o
n
i
c
 
l
y
m
p
h
o
c
y
t
i
c
 
l
e
u
k
e
m
i
a
;
 
C
R
,
 
c
o
m
p
l
e
t
e
 
r
e
s
p
o
n
s
e
;
 
C
T
C
L
,
 
c
u
t
a
n
e
o
u
s
 
T
-
c
e
l
l
 
l
y
m
p
h
o
m
a
;
 
F
D
A
,
 
F
o
o
d
 
a
n
d
 
D
r
u
g
 
A
d
m
i
n
i
s
t
r
a
t
i
o
n
;
 
G
i
,
 
g
a
s
t
r
o
i
n
t
e
s
t
i
n
a
l
;
 
H
D
A
C
,
 
h
i
s
t
o
n
e
 
d
e
a
c
e
t
y
l
a
t
i
o
n
;
 
M
M
,
 
m
u
l
t
i
p
l
e
 
m
y
e
l
o
m
a
;
 
M
T
D
,
 
m
a
x
i
m
u
m
 
t
o
l
e
r
a
t
e
d
 
d
o
s
e
;
 
P
R
,
 
p
a
r
t
i
a
l
 
r
e
s
p
o
n
s
e
;
 
P
T
C
L
,
 
p
e
r
i
p
h
e
r
a
l
 
T
-
c
e
l
l
 
l
y
m
p
h
o
m
a
;
 
R
C
C
,
 
r
e
n
a
l
 
c
e
l
l
 
c
a
r
c
i
n
o
m
a
;
 
S
D
,
 
s
t
a
b
l
e
 
d
i
s
e
a
s
e
.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
Romidepsin in cutaneous T-cell lymphoma
no impact on myocardial function was noted. Analysis of 
the QTc interval before and after treatment demonstrated 
a median QTc prolongation of 14 ms following treatment 
with romidepsin. Some potential explanations that have 
been proposed regarding the asymptomatic electrocardio-
gram abnormalities noted with romidepsin are pretreatment 
with serotonin inhibitors or concurrent use of medications 
known to cause QTc prolongation, electrolyte abnormalities 
of potassium and magnesium known to exist in patients with 
CTCL, and coexistence of comorbidities or pre-existing 
cardiac arrhythmias in the treatment population. Sudden 
death occurred in six patients enrolled in the Phase II trials of 
romidepsin. However, on retrospective analysis, all patients 
had cardiac comorbidities that predisposed them to risk of 
sudden death. With regard to cardiac   dysfunction, clinical tri-
als have excluded patients with pre-existing cardiac disease, 
long QT syndrome, or other risk factors for sudden death. 
Unless this class effect of HDACis is further investigated 
and more experience is gained with their use, it would be 
reasonable to adopt a safe strategy and avoid them in the 
patient population mentioned.
Other unexpected toxicities of romidepsin, including three 
cases of reactivation of latent DNA viruses, have been reported 
in the patients enrolled in the Phase II multi-  institutional study 
of romidepsin in patients with T-cell   lymphoma.40 Two cases of 
Epstein–Barr virus (EBV) associated illness and one case 
of hepatitis B virus (HBV) reactivation were observed. The 
first patient with EBV reactivation died of multiorgan   failure 
from   disseminated EBV infection, and the second patient 
responded well to treatment with   single-agent   rituximab. 
The patient with HBV reactivation was started on treatment 
with single-agent entecavir with a favorable response. It was 
hypothesized that these complications were likely related to 
HDACi therapy through transcriptional activation of silenced 
promoters and induction of   immunosuppression via depletion 
of circulating lymphocytes.
Nausea (all grades 52%–56%), asthenia (all grades 44%), 
anorexia (all grades 20%), vomiting (all grades 19%–26%), 
and aguesia (all grades 13%) were commonly seen in 
patients receiving romidepsin.31,36 Most of these adverse 
events were mild (grade 1 or 2). Only about 2%–7% of the 
patients experienced grade 3 or 4 toxicity, likely secondary 
to administration of serotonin inhibitors prior to and after 
romidepsin infusion.
Constitutional symptoms of fatigue (41%) and fever (25%) 
have been observed in patients on romidepsin treatment and 
felt to be cytokine mediated.31 However, once again, 24% of the 
patients had grade 1 or 2 fatigue, and grade 3 or 4 was rare.
Leukopenia (all grades 30%), granulocytopenia (all 
grades 36%), thrombocytopenia (all grades 40%), and ane-
mia (all grades 37%) were transient and rapidly reversible.31 
Furthermore, romidepsin does not affect the colony-forming 
units from bone marrow cells, and bone marrow biopsies 
performed in patients with romidepsin do not demonstrate 
significant myelosuppression.
Unanswered questions about  
the treatment of CTCL  
with romidepsin
The mechanism behind the efficacy of romidepsin and other 
HDACis as a class in T-cell lymphomas remains unclear. It is 
tempting to speculate that the responsive subset of T-cell 
lymphomas has its origin in an as yet unknown chromosomal 
arrangement that recruits the class I HDACis to the promoter 
of a gene that normally limits cell proliferation. However, 
such chromosomal aberrations have not been described 
in patients with T-cell lymphomas. Hence, it is possible 
that HDACis through their pleiotropic effects are merely 
regulating the balance between cell survival and apoptosis 
in patients with T-cell lymphomas similar to other disease 
entities rather than exerting efficacy via tumor-specific 
mechanisms. Better understanding of tumor biology in CTCL 
and cellular pathways affected by HDACis will be required 
to better define the role of these agents in CTCL, particularly 
in combination therapies. Why responses seen are far more 
common in hematologic malignancies than in solid tumors 
is also not understood.
Differences in the pharmacology, potency, and efficacy 
across HDACis are incompletely understood. Advanced 
pharmacodynamic studies with more clinical experience 
and incorporation of correlative studies into the trials across 
different tumors may answer some of these questions and 
expand the spectrum of activity of romidepsin.
Another pertinent question is the role of synergy between 
romidepsin and other chemotherapeutic agents in diseases 
such as CTCL. HDACis in combination with hypomethalat-
ing agents have shown clinical activity in early-phase clinical 
trials in myeloid malignancies.41–43 Romidepsin has also been 
investigated in combination with the proteasome inhibitor 
bortezomib in patients with relapsed and refractory multiple 
myeloma with encouraging results in a small Phase II trial 
of 22 patients.44 The study showed good tolerability in the 
patients, with four complete responses, two very good partial 
responses, six partial responses, five minimal responses, and 
one stable disease. However, the role of this combination in 
CTCL remains to be explored. Not only will the choice of Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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chemotherapeutic agent be an important area of research in 
such combination strategies but the sequence of administra-
tion will pose a greater challenge given the lack of clear 
understanding of the molecular effects of HDACis.
Given the plethora of HDACis now available for 
clinical use, molecular analysis of tumors for signatures 
that can predict sensitivity response to individual agents 
would be ideal. A retrospective analysis of pretreatment 
CTCL skin biopsies found that high nuclear STAT1 and 
phopho-STAT3 staining in lymphoma cells correlated 
with a lack of clinical response to vorinostat.45 Although 
the status of STAT1 and phosphor-STAT3 as predictors 
of romidepsin response remains unknown, identification 
of such biomarkers that could predict the outcome of 
romidepsin in patients with CTCL should be a focus of 
future clinical trials.
Finally, given the promising activity of all HDACis in 
CTCL, it is important to compare them with one another 
either as single agents or in combination with other therapies 
in Phase III trials to see whether one drug emerges to have 
superior efficacy or use molecular analysis to tailor thera-
pies for individual patients. Comparative efficacy, toxicity, 
and cost effectiveness between the two FDA-approved and 
indicated HDACi therapies romidepsin and vorinostat for 
CTCL have not been studied.
Identification of ways to exploit the use of romidepsin in 
solid tumors and combination with radiation will be needed 
to select cell types that are sensitive to the poorly understood 
epigenetic modifications induced by romidepsin.
Conclusion
Despite multiple unresolved questions with respect to the 
mechanism of action of romidepsin in CTCL and the fact 
that it is not a targeted therapy, romidepsin has demonstrated 
significant clinical activity in patients with refractory neo-
plasms such as MF and SS with good durability and tolerable 
side effects. We anticipate future trials comparing its role 
either as a single agent or in combination with other biologic 
agents in both frontline and relapsed settings. Designing and 
implementing randomized multicenter clinical trials with 
laboratory correlates to investigate the efficacy of drugs for 
rare diseases like CTCL will always be a challenge. Hence, 
it is imperative that insight into the biology of CTCL guides 
the development of novel agents.
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